New Aortic Data Demonstrates Medtronic`s Commitment to Innovation
DUBLIN - November 16, 2015 - Medtronic plc (MDT) today announced notable clinical studies and innovative technologies that will be presented at the annual VEITHsymposium, the world`s premier conference for vascular surgeons specializing in the most current information and new developments in clinical practice and research. The conference is taking place in New York City from November 17-21, 2015.
"Leveraging decades of clinical experiences and data, our core technologies for treating abdominal aortic aneurysm (AAA) and descending thoracic disease, Endurant® and Valiant® product lines, have been proven in more than 280,000 patients globally," said Daveen Chopra, vice president and general manager of the Aortic business, which is part of the Aortic & Peripheral Vascular division at Medtronic. "Our mission to improve patient outcomes drives our commitment to build on our success and invest in complementary innovative technology that will allow physicians to treat more complex aortic disease."
The VEITHsymposium will begin with a special session focusing on new developments in AAA and endovascular aneurysm repair (EVAR). This session will feature the highly anticipated four-year subset results on hostile neck anatomies from the ENGAGE Global Registry for Medtronic`s Endurant AAA stent graft system. Hence J.M. Verhagen, M.D., Ph.D., Professor and Chief of Vascular Surgery, Erasmus University Medical Center in Rotterdam, the Netherlands, will present this real-world data on the opening day of VEITH. Additionally, four-year results from the full ENGAGE registry cohort will be presented on Saturday, November 21, 2015, by Marc R.H.M van Sambeek, M.D., Ph.D, Department of Vascular Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Medtronic`s recently acquired EndoAnchor system will also be highlighted in nine presentations examining clinical applicability. The Heli-FX® EndoAnchor® system is an endovascular deployed anchor designed to attach a variety of aortic endografts to the native vessel wall.
Finally, several Medtronic products in clinical trials will be highlighted, such as the Endurant® Evo AAA stent graft system, as well as products for complex aortic disease, including:
Modified Valiant devices used in the treatment of ascending arch disease.
One-year results from the early feasibility of the Valiant "Mona LSA®" branch thoracic stent graft system.
The initial experience in the treatment of thoracoabdominal with modified Medtronic stent grafts.
Tuesday, November 17
6:51 am - 6:56 am Redefining Adverse Neck Morphology With Newer EVAR Devices Which Perform Better In Short, Angulated, and Large Diameter Necks And Those With A Thrombus Burden: What Are the Limits?, from the ENGAGE Registry
7:20 am - 7:25 am Endograft Repair Of Ascending Aortic Lesions And Type A Dissections With A Physician Sponsored IDE (PSIDE) For A Modified Valiant Device: Lessons Learned And What Are The Prospects For An Endograft-Valve Combined Device?
Noon - 1 pm Treating Challenging Anatomies in TEVAR and EVAR. New York Hilton Midtown, Gramercy West 2nd Floor, a Medtronic sponsored event
Wednesday, November 18
9:05am - 9:09 am DEBATE: EVAR With Short Necks Are Best Treated With Standard EVAR Using Newer Endograft Devices
Thursday, November 19
7:46am - 7:51am Newly Modified Medtronic Endurant (Evo) Endograft (investigational device): Initial Clinical Experience And Advantages
10:17am - 10:22am A New Manifold Branched Endograft Device (investigational device) For Treating TAAAs And Other Complex Aortic Lesions: Concept, Advantages, Initial Clinical Experience
11:26am - 11:31am The Medtronic Branched TEVAR Endograft, The Valiant Mona LSA System (investigational device): Technique, Advantages and Results
3:40pm - 4:47pm Session 61: Preventing And Treating Migration and Endoleaks: Update on Heli-Fx EndoAnchors
Details such as times, titles and locations are subject to change.
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.
About VEITH symposium
Now in its 42nd year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. For more information, please visit www.VEITHpress.org or contact Pauline T. Mayer at 631.979.3780.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic`s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medtronic plc via GlobeNewswire